Plasma Resilience: Europe's Lifeline
Human plasma, a protein-rich liquid making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Despite its importance, Europe's plasma supply chain is vulnerable, relying on donations from over 12 million people annually, governed by EU and international safety standards, such as the International Quality Plasma Program (IQPP) and overseen by the Plasma Protein Therapeutics Association (PPTA).
However, this is not sufficient, as nearly 40% of plasma used in European medicine production is imported from the United States.
Plasma is singularly human, existing only thanks to the generosity of real people, unlike many lab-produced therapies.
Autor's resume: Plasma resilience is Europe's lifeline.
More News
- UVA faculty rejects Trump administration's Compact for Academic Excellence
- A Saint for our time: The canonization of Archbishop Ignatius Maloyan
- Brio and Bravo get strategic investment from R&R Brands
- Trump Has Merged the War on Gangs and Immigration. Tennessee Shows How.
- Coast Guard and National Guard crews have now rescued 51 from Alaska floods
- Perfect Pitch: The Life of a Showgirl
- The most dangerous intersections in Los Angeles
- Martin won't give up on Stawell dream, but for now the 400m is his focus
- Rugby Shirts Are the Latest Preppy Trend Making a Comeback—Here Are the Best Ones to Shop
- Brendan Gallagher: No-one is immune to this awful disease